6831-55-6

Usage

Uses

Used in Pharmaceutical Industry:
(3,4-DICHLORO-PHENYL)-ACETYL CHLORIDE is used as a reagent for introducing the acetyl functional group into various organic molecules, which is essential in the synthesis of many pharmaceutical compounds.
Used in Agrochemical Industry:
(3,4-DICHLORO-PHENYL)-ACETYL CHLORIDE is used as a building block in the production of various agrochemicals, contributing to the development of effective pesticides and other agricultural products.
Used in Organic Synthesis:
(3,4-DICHLORO-PHENYL)-ACETYL CHLORIDE is used as a reagent in organic synthesis for the introduction of the acetyl functional group into organic molecules, enabling the creation of a wide range of chemical products.

Upstream product

• 1805-32-9 3,4-dichlorobenzyl alcohol 
• 79-37-8 oxalyl dichloride 
• 5807-30-7 3,4-dichlorophenyl acetic acid 
• 121639-61-0 3,4-difluorophenylacetyl chloride 
• 23722-52-3 2-diazo-1-(3,4-dichlorophenyl)ethan-1-one 
• 3024-72-4 3,4-dichlorobenzoyl chloride 
• 51-44-5 3,4-dichlorbenzoic acid 
• 18880-04-1 3,4-dichlorobenzyl bromide 
• 3218-49-3 3,4-dichloro-benzeneacetonitrile 
• 106-46-7 para-dichlorobenzene 
• 79-04-9 chloroacetyl chloride 

Downstream Products

• 67197-92-6 2-(3,4-Dichloro-phenyl)-N-((1S,2S)-2-dimethylamino-cyclohexyl)-N-methyl-acetamide 
• 116763-50-9 N-[2-(3,4-dichlorophenyl)acetyl]-N-methyl-2-(1-pyrrolidinyl)ethylamine 
• 135709-59-0 2-(3,4-Dichloro-phenyl)-1-(2-pyrrolidin-1-ylmethyl-3,4-dihydro-2H-quinolin-1-yl)-ethanone 
• 130013-58-0 2-(3,4-dichlorophenyl)-N-methyl-N-<(2S)-2-methyl-2-(1-pyrrolidinyl)ethyl>acetamide 
• 118045-77-5 2-(3,4-Dichloro-phenyl)-1-[2-(1-dimethylamino-ethyl)-piperidin-1-yl]-ethanone 
• 118045-77-5 2-(3,4-Dichloro-phenyl)-1-[2-(1-dimethylamino-ethyl)-piperidin-1-yl]-ethanone 
• 130013-59-1 2-(3,4-Dichloro-phenyl)-N-(1,1-dimethyl-2-pyrrolidin-1-yl-ethyl)-N-methyl-acetamide; hydrochloride 
• 130497-15-3 2-(3,4-Dichloro-phenyl)-1-((S)-2-diethylaminomethyl-piperidin-1-yl)-ethanone 
• 115199-69-4 ICI 197067 hydrochloride 
• 130013-57-9 2-(3,4-Dichloro-phenyl)-N-methyl-N-((R)-1-methyl-2-pyrrolidin-1-yl-ethyl)-acetamide; hydrochloride 
• 136328-87-5 2-(3,4-Dichloro-phenyl)-N-methyl-N-((S)-3-methyl-1-pyrrolidin-1-ylmethyl-butyl)-acetamide 
• 136328-88-6 2-(3,4-Dichloro-phenyl)-N-(2,2-dimethyl-1-pyrrolidin-1-ylmethyl-propyl)-N-methyl-acetamide 
• 115199-96-7 2-(3,4-Dichloro-phenyl)-N-(2,2-dimethyl-1-pyrrolidin-1-ylmethyl-propyl)-N-methyl-acetamide; hydrochloride 
• 130497-38-0 2-(3,4-Dichloro-phenyl)-1-((S)-2-piperidin-1-ylmethyl-piperidin-1-yl)-ethanone 

Relevant academic research and scientific papers

Pentuline derivatives and preparation methods and applications thereof

The present invention provides a chingotine derivative, the structural formula of which is shown in formula I. Specifically, the R is any of the following groups: p-chlorophenylacetyl, 2,4-dichlorophenylacetyl, m-chlorophenylacetyl, 3,4-dichlorophenylacet

Identification of BR102910 as a selective fibroblast activation protein (FAP) inhibitor

Fibroblast activation protein (FAP) belongs to the family of prolyl-specific serine proteases and displays both exopeptidase and endopeptidase activities. FAP expression is undetectable in most normal adult tissues, but is greatly upregulated in sites of tissue remodeling, which include fibrosis, inflammation and cancer. Due to its restricted expression pattern and dual enzymatic activities, FAP inhibition is investigated as a therapeutic option for several diseases. In the present study, we described the structure–activity relationship of several synthesized compounds against DPPIV and prolyl oligopeptidase (PREP). In particular, BR102910 (compound 24) showed nanomolar potency and high selectivity. Moreover, the in vivo FAP inhibition study of BR102910 (compound 24) using C57BL/6J mice demonstrated exceptional profiles and satisfactory FAP inhibition efficacy. Based on excellent in vitro and in vivo profiles, the potential of BR102910 (compound 24) as a lead candidate for the treatment of type 2 diabetes is considered.

Design, synthesis, biological evaluation and silico prediction of novel sinomenine derivatives

Sinomenine is a morphinan alkaloid with a variety of biological activities. Its derivatives have shown significant cytotoxic activity against different cancer cell lines in many studies. In this study, two series of sinomenine derivatives were designed and synthesized by modifying the active positions C1 and C4 on the A ring of sinomenine. Twenty‐three compounds were synthesized and characterized by spectroscopy (IR,1H‐NMR,13C‐NMR, and HRMS). They were further evaluated for their cytotoxic activity against five cancer cell lines, MCF‐7, Hela, HepG2, SW480 and A549, and a normal cell line, Hek293, using MTT and CCK8 methods. The chlorine‐containing compounds exhibited significant cytotoxic activity compared to the nucleus structure of sinomenine. Furthermore, we searched for cancer‐related core targets and verified their interaction with derivatives through molecular docking. The chlorine‐containing compounds 5g, 5i, 5j, 6a, 6d, 6e, and 6g exhibited the best against four core targets AKT1, EGFR, HARS and KARS. The molecular docking results were consistent with the cytotoxic results. Overall, results indicate that chlorine‐containing derivatives might be a promising lead for the development of new anticancer agents.

Enantioselective Synthesis of 2-Functionalized Tetrahydroquinolines through Biomimetic Reduction

Biomimetic asymmetric reduction of 2-functionalized quinolines has been successfully developed with the chiral and regenerable NAD(P)H model CYNAM in the presence of transfer catalyst simple achiral phosphoric acids, providing the chiral 2-functionalized

N-monoarylacetothioureas as potent urease inhibitors: synthesis, SAR, and biological evaluation

A urease inhibitor with good in vivo profile is considered as an alternative agent for treating infections caused by urease-producing bacteria such as Helicobacter pylori. Here, we report a series of N-monosubstituted thioureas, which act as effective urease inhibitors with very low cytotoxicity. One compound (b19) was evaluated in detail and shows promising features for further development as an agent to treat H. pylori caused diseases. Excellent values for the inhibition of b19 against both extracted urease and urease in intact cell were observed, which shows IC50 values of 0.16 ± 0.05 and 3.86 ± 0.10 μM, being 170- and 44-fold more potent than the clinically used drug AHA, respectively. Docking simulations suggested that the monosubstituted thiourea moiety penetrates urea binding site. In addition, b19 is a rapid and reversible urease inhibitor, and displays nM affinity to urease with very slow dissociation (koff=1.60 × 10?3 s?1) from the catalytic domain.

Synthesis of novel nicotinic ligands with multimodal action: Targeting Acetylcholine α4β2, Dopamine and Serotonin Transporters

Nicotinic acetylcholine receptors (nAChRs), serotonin transporters (SERT) and dopamine transporters (DAT) represent targets for the development of novel nicotinic derivatives acting as multiligands associated with different health conditions, such as depressive, anxiety and addiction disorders. In the present work, a series of functionalized esters structurally related to acetylcholine and nicotine were synthesized and pharmacologically assayed with respect to these targets. The synthesized compounds were studied in radioligand binding assays at α4β2 nAChR, h-SERT and h-DAT. SERT experiments showed not radioligand [3H]-paroxetine displacement, but rather an increase in the radioligand binding percentage at the central binding site was observed. Compound 20 showed Ki values of 1.008 ± 0.230 μM for h-DAT and 0.031 ± 0.006 μM for α4β2 nAChR, and [3H]-paroxetine binding of 191.50% in h-SERT displacement studies, being the only compound displaying triple affinity. Compound 21 displayed Ki values of 0.113 ± 0.037 μM for α4β2 nAChR and 0.075 ± 0.009 μM for h-DAT acting as a dual ligand. Molecular docking studies on homology models of α4β2 nAChR, h-DAT and h-SERT suggested potential interactions among the compounds and agonist binding site at the α4/β2 subunit interfaces of α4β2 nAChR, central binding site of h-DAT and allosteric modulator effect in h-SERT.

Discovery and evolution of aloperine derivatives as novel anti-filovirus agents through targeting entry stage

Preventing filoviruses in the entry stage is an attractive antiviral strategy. Taking aloperine, a Chinese natural herb with an endocyclic skeleton, as the lead, 23 new aloperine derivatives were synthesized and evaluated for their anti-filovirus activiti

Structural insight into the optimization of ethyl 5-hydroxybenzo[g]indol-3-carboxylates and their bioisosteric analogues as 5-LO/m-PGES-1 dual inhibitors able to suppress inflammation

The release of pro-inflammatory mediators, such as prostaglandines (PGs) and leukotrienes (LTs), arising from the arachidonic acid (AA) cascade, play a crucial role in initiating, maintaining, and regulating inflammatory processes. New dual inhibitors of 5-lipoxygenase (5-LO) and microsomal prostaglandin E2 synthase-1 (mPGES-1), that block, at the same time, the formation of PGE2 and LTs, are currently emerged as a highly interesting drug candidates for better pharmacotherapie of inflammation-related disorders. Following our previous studies, we here performed a detailed structure-based design of benzo[g]indol-3-carboxylate derivatives, disclosing several new key factors that affect both enzyme activity. Ethyl 2-(3,4-dichlorobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate (4b, RAF-01) and ethyl 2-(3,4-dichlorophenyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate (7h, RAF-02) emerged as the most active compounds of the series. Additionally, together with selected structure based analogues, both derivatives displayed significant in vivo anti-inflammatory properties. In conclusion, modeling and experimental studies lead to the discovery of new candidate compounds prone to further developments as multi-target inhibitors of the inflammatory pathway.

Discovery of a potent protein kinase D inhibitor: insights in the binding mode of pyrazolo[3,4-d]pyrimidine analogues

In this study, we set out to rationally optimize PKD inhibitors based on the pyrazolo[3,4-d]pyrimidine scaffold. The lead compound for this study was 1-NM-PP1, which was previously found by us and others to inhibit PKD. In our screening we identified one compound (3-IN-PP1) displaying a 10-fold increase in potency over 1-NM-PP1, opening new possibilities for specific protein kinase inhibitors for kinases that show sensitivity towards pyrazolo[3,4-d]pyrimidine derived compounds. Interestingly the observed SAR was not in complete agreement with the commonly observed binding mode where the pyrazolo[3,4-d]pyrimidine compounds are bound in a similar fashion as PKD's natural ligand ATP. Therefore we suggest an alternate binding mode where the compounds are flipped 180 degrees. This possible alternate binding mode for pyrazolo[3,4-d]pyrimidine based compounds could pave the way for a new class of specific protein kinase inhibitors for kinases sensitive towards pyrazolo[3,4-d]pyrmidines.

Ruthenium-catalysed one-pot regio- and diastereoselective synthesis of pyrrolo[1,2-a] indoles via cascade C-H functionalization/annulation

A cascade approach has been developed towards dual C-C bond formation via consecutive C-H functionalization/cyclization giving access to pyrrolo[1,2-a]indoles in a highly regio- and diastereoselective manner using catalytic [Ru(p-cymene)Cl2]2. The methodology was further expanded to attain pentacyclic structures involving manifold C-C bond creation.